A Randomized Phase III Study Evaluating the Continuation of Bevacizumab (BV) Beyond Progression in Metastatic Colorectal Cancer (MCRC) Patients (PTS) Who Received BV as Part of First-Line Treatment: Results of the Bebyp Trial by the Gruppo Oncologico Nord Ovest (GONO)

Phase Iii ◽

Line Treatment ◽

First Line ◽

Treatment Results ◽

Phase Iii Study ◽

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdz155.033 ◽

2019 ◽

Vol 30 ◽

pp. iv10

Author(s):

K. Muro ◽

H. Uetake ◽

K. Tsuchihara ◽

K. Shitara ◽

K. Yamazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Phase Iii Study ◽

Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/− celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3525 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3525-3525 ◽

Cited By ~ 12

Author(s):

C.-H. Kohne ◽

J. de Greve ◽

C. Bokemeyer ◽

I. Lang ◽

P. Vergauwe ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps3625 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS3625-TPS3625 ◽

Cited By ~ 1

Author(s):

Kei Muro ◽

Hiroyuki Uetake ◽

Katsuya Tsuchihara ◽

Kohei Shitara ◽

Kentaro Yamazaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Phase Iii Study ◽

104P Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study

Annals of Oncology ◽

10.1016/j.annonc.2020.10.124 ◽

2020 ◽

Vol 31 ◽

pp. S1282

Author(s):

S. Qin ◽

J. Li ◽

Y. Bai ◽

Y. Shu ◽

W. Li ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Safety And Efficacy ◽

Phase Iii Study ◽

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdu141 ◽

2014 ◽

Vol 25 (7) ◽

pp. 1346-1355 ◽

Cited By ~ 258

Author(s):

J.Y. Douillard ◽

S. Siena ◽

J. Cassidy ◽

J. Tabernero ◽

R. Burkes ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

636 POSTER Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80932-2 ◽

2005 ◽

Vol 3 (2) ◽

pp. 179-180 ◽

Cited By ~ 1

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Case Medical Research ◽

10.31525/ct1-nct03869892 ◽

2019 ◽

Author(s):

Keyword(s):

Colorectal Cancer ◽

Intensive Therapy ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Annals of Oncology ◽

10.1093/annonc/mdw206 ◽

2016 ◽

Vol 27 (8) ◽

pp. 1539-1546 ◽

Cited By ~ 75

Author(s):

K. Yamazaki ◽

M. Nagase ◽

H. Tamagawa ◽

S. Ueda ◽

T. Tamura ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

6001 International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71096-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 321 ◽

Cited By ~ 1

Author(s):

N. Tebbutt ◽

V. Gebski ◽

K. Wilson ◽

M. Cummins ◽

B. Robinson ◽

...

Keyword(s):

Colorectal Cancer ◽

Mitomycin C ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study

BioDrugs ◽

10.1007/s40259-021-00484-9 ◽

2021 ◽

Author(s):

Shukui Qin ◽

Jin Li ◽

Yuxian Bai ◽

Yongqian Shu ◽

Wei Li ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Study ◽